A number of cannabinoid compounds are being sold in the form of incense as 'legal' alternatives to marijuana. The purpose of these experiments was to determine whether the most common of these compounds have discriminative stimulus effects similar to Δ 9 -tetrahydrocannabinol (Δ 9 -THC), the main active component in marijuana. Locomotor depressant effects of JWH-018, JWH-073, JWH-200, JWH-203, JWH-250, AM-2201, and CP 47,497-C8-homolog were tested in mice. The compounds were then tested for substitution in rats trained to discriminate Δ 9 -THC (3 mg/kg, intraperitoneally). The time course of the peak dose of each compound was also tested. Each of the synthetic cannabinoids dose-dependently decreased locomotor activity for 1-2 h. Each of the compounds fully substituted for the discriminative stimulus effects of Δ 9 -THC, mostly at doses that produced only marginal amounts of rate suppression. JWH-250 and CP 47,497-C8-homolog suppressed response rates at doses that fully substituted for Δ 9 -THC. The time courses varied markedly between compounds. Most of the compounds had a shorter onset than Δ 9 -THC, and the effects of three of the compounds lasted substantially longer and CP 47,. Several of the most commonly used synthetic cannabinoids produce behavioral effects comparable with those of Δ 9 -THC, which suggests that these compounds may share the psychoactive effects of marijuana responsible for abuse liability. The extremely long time course of the discriminative stimulus effects and adverse effects of CP 47,497-C8-homolog suggest that CP 47,497-C8-homolog may be associated with increased hazards among humans. Behavioural Pharmacology 25:750-757 Time course of the discriminative stimulus effects of synthetic cannabinoids. Percentage of total responses made on the drug-appropriate lever as a function of time. Each panel shows the effects of the peak dose of compound. JWH-073, n = 8; AM-2201, n = 8; CP 47,497-C8-homolog, n = 9; otherwise, n = 6, except where shown.
Introduction
A number of synthetic cannabinoid compounds are being sold in the form of incense as a quasilegal alternative to marijuana using names such as 'K2' or 'Spice' (Lindigkeit et al., 2009; Fattore and Fratta, 2011) . The use of these compounds seems to be increasing; for example, JWH-018 and JWH-073 were found in 4.5% of recent blood samples from US athletes (Heltsley et al., 2012) , and a variety of synthetic cannabinoids including AM-2201 and JWH-018 have been detected in blood samples of people ticketed for driving under the influence (Musshoff et al., 2014) . Clinical case studies have indicated that these substances produce cannabis-like effects, and can lead to dependence on repeated administration and elicit withdrawal signs upon cessation of use in humans (Zimmermann et al., 2009; Gunderson et al., 2012) . There is at least one possible case of seizures after consumption of large doses of synthetic cannabinoids obtained over the Internet (Tofighi and Lee, 2012) .
In January 2012, the Drug Enforcement Agency temporarily scheduled four synthetic cannabinoids that were deemed of particular concern, JWH-073, JWH-018, JWH-200, and CP 47,497 (Office of Forensic Sciences, 2010) . Other synthetic cannabinoids have since become more visible, and some of the synthetic cannabinoids most commonly found in seized samples of herbal incense include JWH-018, JWH-073, JWH-200, JWH-250, CP 47,497, and AM-2201 (Logan et al., 2012; Denooz et al., 2013 ).
An increasing number of studies have examined the pharmacology of JWH-018 and JWH-073, but little work has been conducted on JWH-200, JWH-250, CP 47,497, and AM-2201. Compounds of this structural class are known to produce effects at cannabinoid CB1 receptors, despite having structures different from Δ 9 -tetrahydrocannabinol (Δ 9 -THC). JWH-018, JWH-073, and CP 47,497-C8-homolog bind to cannabinoid CB1 receptors, inhibit neurotransmission in hippocampal neurons, and facilitate cannabinoid CB1 receptor internalization (Showalter et al., 1996; Atwood et al., 2010 Atwood et al., , 2011 Brents et al., 2012) . In addition, JWH-018 and JWH-073 bind to human cannabinoid CB2 receptors and act as agonists (Rajasekaran et al., 2013) . As JWH-018 and JWH-073 share their mechanism of action with Δ 9 -THC, a major active component of marijuana, it is not surprising that they fully substituted for the discriminative stimulus effects of Δ 9 -THC in rhesus monkeys and that the monkeys developed cross-tolerance to JWH-018 and JWH-073 following repeated administration of Δ 9 -THC . In addition, JWH-018 and JWH-073 substituted for the discriminative stimulus effects of Δ 9 -THC in rats (Järbe et al., 2011; Wiley et al., 2014) and mice Marshell et al., 2014) and suppressed locomotor activity in mice (Wiley et al., 1998) .
The purpose of the present study was to assess the potential abuse liability of several of the most commonly found synthetic cannabinoids: JWH-018, JWH-073, JWH-200, JWH-203, JWH-250, AM-2201, and CP 47,497-C8-homolog. The locomotor depressant effects of these compounds were tested to find behaviorally active dose ranges and time courses of these compounds. Subsequently, the compounds were tested in the drug discrimination assay, which is a useful animal model for detecting compounds that share subjective effects of known drugs of abuse (Balster, 1991) and is predictive of abuse liability (Horton et al., 2013) . Rats were trained to discriminate Δ 9 -THC from vehicle, and the dose effect and time course of these synthetic cannabinoids were assessed.
Methods

Subjects
Male Swiss-Webster mice were obtained from Harlan (Indianapolis, Indiana, USA) at ∼ 8 weeks of age and tested at ∼ 10 weeks of age. Mice were group housed in cages on a 12 : 12-h light/dark cycle and were allowed free access to food and water. Male Sprague-Dawley rats were obtained from Harlan Laboratories (Indianapolis, Indiana, USA). All rats were housed individually and were maintained on a 12 : 12-h light/dark cycle (lights on at 07:00 h). Body weights were maintained at 320-350 g by limiting food to 15 g/day, which included the food received during operant sessions. Water was readily available. All housing conditions and procedures were in accordance with the Guidelines for the Care and Use of Laboratory Animals (National Research Council, 2011) and were approved by the University of North Texas Health Science Center Animal Care and Use Committee.
Locomotor activity
The study was conducted using 40 Digiscan (model RXYZCM; Omnitech Electronics, Columbus, Ohio, USA) locomotor activity testing chambers (40.5 × 40.5 × 30.5 cm) housed in sets of two within sound-attenuating chambers. A panel of infrared beams (16 beams) and corresponding photodetectors was located in the horizontal direction along the sides of each activity chamber. A 7.5 W incandescent light above each chamber provided dim illumination and fans provided an 80 dB ambient noise level within the chamber.
Separate groups of eight mice each were injected with either vehicle (ethanol/cremophor EL/0.9% saline 1 : 1 : 18) or cannabinoid: Δ 9 -THC (1, 3, 10, or 30 mg/kg), JWH-018 (0.03, 0.1, 0.3, or 1 mg/kg), JWH-073 (0.3, 1, 3, or 10 mg/kg), JWH-200 (0.3, 1, 3, or 10 mg/kg), JWH-203 (0.3, 1, 3, or 10 mg/kg), JWH-250 (1, 3, 10, or 30 mg/kg), AM-2201 (0.1, 0.3, 1, or 3 mg/kg), CP 47,497-C8-homolog (0.3, 1, 3, or 10 mg/kg), immediately before locomotor activity testing. In all studies, horizontal activity (interruption of photocell beams) was measured for 8 h in 10 min intervals, beginning at 08:00 h (1 h after lights on). Behavioral observations from each mouse were recorded at 30, 120, and 480 min after the highest dose tested.
Discrimination procedures
Standard behavior-testing chambers (Coulbourn Instruments, Allentown, Pennsylvania, USA) were connected to IBM-PC compatible computers through LVB interfaces (Med Associates, East Fairfield, Vermont, USA). The computers were programmed in Med-PC for Windows, version IV (Med Associates) for the operation of the chambers and collection of data.
Using a two-lever choice methodology, a pool of rats previously trained to discriminate Δ 9 -THC (3 mg/kg) from vehicle (ethanol/cremophor EL/0.9% saline 1 : 1 : 18) were tested. Rats received an injection of either saline or drug and were subsequently placed in the behavior-testing chambers, in which food (45 mg food pellets; Bio-Serve, Frenchtown, New Jersey, USA) was available as a reinforcer for every 10 responses on a designated injection-appropriate lever. The pretreatment time was 30 min. Each training session lasted a maximum of 10 min, and the rats could earn up to 20 food pellets. The rats underwent ∼ 60 of these sessions before they were used in tests for substitution of the experimental compounds. Rats were used in testing once they had achieved 85% injection-appropriate responding in nine of 10 sessions for both the first reinforcer and the total session. The training sessions were conducted on separate days in a double alternating manner (drug-drug-vehicle-vehicle-drug, etc.) until the training phase was complete, after which substitution tests were introduced into the training schedule such that at least one vehicle and one drug session were conducted between each test (drug-vehicle-test-vehicle-drug-test-drug, etc.). The substitution tests were performed only if the rats had achieved 85% injection-appropriate responding in the two prior training sessions.
During test sessions, both levers were active, such that 10 consecutive responses on either lever led to reinforcement. For dose-effect experiments, data were collected until the first reinforcer was obtained, or for a maximum of 20 min. Each compound was tested in groups of six rats, except Δ 9 -THC (n = 13) and JWH-073 (n = 7). A repeated-measures design was used, such that each rat was tested at all doses of a given drug. Intraperitoneal injections (1 ml/kg) of vehicle, Δ 9 -THC (0.1-3 mg/kg), JWH-018 (0.05-0.5 mg/kg), JWH-073 (0.1-10 mg/kg), JWH-200 (0.1-5 mg/kg), JWH-203 (0.5-10 mg/kg), JWH-250 (0.25-5 mg/kg), and CP 47,497-C8-homolog (0.1-2.5 mg/kg) were administered 30 min before the start of the test session. AM-2201 (0.05-0.5 mg/kg) was administered 20 min before the start of the test session. Doses were tested in no particular order.
For time course experiments, a repeated-measures design was used, such that each rat was tested at several time points following a single administration of the test compound. The rats were injected with the test compound and placed in the test chamber 5 min after administration. Data were collected until the first reinforcer was obtained, or for a maximum of 5 min, and the rats were immediately removed from the chambers. Testing was repeated at 15, 30, 60, and 120 min after administration. If necessary, testing was continued at 4, 8, 24, and 48 h after administration, until THC-appropriate responding had decreased to below 30-40%.
were provided by the National Institute on Drug Abuse Drug Supply Program. All drugs were dissolved in ethanol/cremophor EL/0.9% saline (1 : 1 : 18) and were administered intraperitoneally in a volume of 1 ml/kg.
Data analysis
Drug discrimination data are expressed as the mean percentage of drug-appropriate responses occurring in each test period. Rates of responding were expressed as a function of the number of responses made divided by the time to the first reinforcer. Graphs for percent drugappropriate responding and response rate were plotted as a function of the dose of the test compound (log scale). Percent drug-appropriate responding was shown only if at least three rats completed the first fixed ratio, whereas response rate data are shown for all rats. Full substitution was defined as 80% or higher drug-appropriate responding, which was not statistically different from that of the training drug.
The potencies of JWH-018, JWH-073, JWH-200, JWH-203, JWH-250, AM-2201, and CP 47,497-C8-homolog were calculated by fitting straight lines to the dose-response data for each compound using TableCurve 2D (Jandel Scientific, San Rafael, California, USA). Straight lines were fitted to the linear portion of the dose-effect curves, including not more than one dose producing less than 20% of the maximal effect and not more than one dose producing greater than 80% of the maximal effect. Other doses were excluded from the analyses. Differences in ED 50 values were tested by one-way analysis of variance followed by Tukey's test to compare individual means. Response rate data were analyzed by one-way repeated-measures analysis of variance. Effects of individual doses were compared with the vehicle control value using a-priori contrasts. The criterion for significance was set a priori at P less than 0.05.
Locomotor activity data were expressed as the mean number of photocell counts in the horizontal plane (ambulation counts) during each 10-min period of testing. A 30-min period, beginning when maximal depression of locomotor activity first appeared as a function of dose, was used for analysis of dose-response data and calculation of ED 50 values. TableCurve 2D was used to estimate the maximal depression under each cannabinoid. The ED 50 values were then calculated by estimating the dose producing 50% of the maximal depression from the descending linear portion of the dose-response curve. A two-way repeated-measures analysis of variance (dose × time) was carried out on horizontal activity counts/10-min interval. A one-way analysis of variance was carried out on horizontal activity counts for the 30-min period of maximal effect, and planned comparisons were made for each dose against saline control using single degree-offreedom F-tests. The ED 50 values of the cannabinoids in the discrimination and locomotor activity assays were compared by least squares regression analysis using Excel 2007 (Microsoft, Redmond, WA, USA). Table 1 shows the ED 50 values. Each compound produced decreases in locomotor activity as the dose increased. A twoway analysis of variance was carried out on data from each compound, yielding a significant main effect of treatment, as well as a treatment × time period interaction (all Ps < 0.01). Treatment with Δ 9 -THC resulted in time-dependent and dose-dependent depression of locomotor activity. Depressant effects were seen at doses of 3-30 mg/kg from 10 to 40 min [F(6,57) = 4.85, P < 0.001] and from 90 to 120 min [F(6,57) = 3.34, P < 0.001]. The apparent stimulant effect from 30 to 60 min following administration of 0.3, 1, and 3 mg/kg Δ 9 -THC was not statistically significant. No unusual effects were observed during the observation periods. Δ 9 -THC-like effects of K2/Spice compounds Gatch and Forster 753 doses of 1-10 mg/kg. Depressant effects of 1-10 mg/kg AM-2201 were observed within 10-30 min after injection and lasted 120 min, with maximal suppression at 30-60 min [F(4,35) = 21.01, P < 0.001].
Results
Locomotor activity
Discrimination JWH-018, JWH-073, JWH-200, JWH-203, JWH-250, AM-2201, and CP 47,497-C8-homolog each produced dose-dependent full substitution for the discriminative stimulus effects produced by 3 mg/kg Δ 9 -THC (Fig. 2) . ED 50 values are shown in Table 1 . The cannabinoids were less potent in the locomotor activity assay compared with the discrimination assay, but there was no correlation between the potencies of the cannabinoids in the discrimination and locomotor activity assays [r 2 = 0.33, P = 0.14]. JWH-018, JWH-200, JWH-203, JWH-250, and AM-2201 failed to alter response rates at the doses tested. JWH-073 increased response rate at a dose of 1 mg/kg and decreased response rate at a dose of 10 mg/kg [F(5,30) = 7.16, P < 0.001]. Four of seven rats failed to complete the first fixed ratio when tested at 10 mg/kg JWH-073. CP 47,497-C8-homolog [F(5,25) = 3.91, P = 0.009] decreased the response rate at the highest dose tested (2.5 mg/kg).
Δ 9 -THC produced full substitution (>80%) by 30 min after administration, which lasted 4 h (Fig. 3) . The discriminative stimulus effects of Δ 9 -THC disappeared 8 h after administration. JWH-018 produced full substitution for the discriminative stimulus effects of Δ 9 -THC at 15 and 60 min after administration, with effects gradually diminishing at 2 and 4 h after administration. JWH-073 produced full substitution at 30 and 60 min after administration, with effects diminishing from 2 to 8 h after administration. Little or no substitution was seen for Δ 9 -THC at 24 h after administration. JWH-200 showed a more rapid onset, producing 60% drug-appropriate responding at 5 min after administration. Full substitution was observed from 30 to 60 min after administration, and drug-appropriate responding diminished over the next 7 h.
JWH-203 was relatively short-acting, producing full substitution for the discriminative stimulus effects of Δ 9 -THC at 30 min after administration, whereas drugappropriate responding decreased to 5% by 2 h after administration (Fig. 3) . JWH-250 produced full substitution within 5 min, but the full substitution lasted for 2 h before drug-appropriate responding dropped to ∼ 50% at 2 and 4 h after administration. Effects of JWH-250 were at 10% drug-appropriate responding at 24 h after administration. AM-2201 also produced full substitution within 5 min after administration, and drugappropriate responding diminished over the 8 h of testing. CP 47,497-C8-homolog had a relatively slow onset, producing 40% drug-appropriate responding at 15 min after administration, 80% at 30 and 60 min, and 100% at 2-8 h, dropping to 80% drug-appropriate responding at 24 h, and its effects had dissipated at 48 h after administration.
Discussion
Synthetic cannabinoids found in gray-market compounds were found to be behaviorally active. All seven compounds (JWH-018, JWH-073, JWH-200, JWH-203, JWH-250, AM-2201, and CP 47,497-C8-homolog) dosedependently decreased locomotor activity. The degree of effect and the time courses of these compounds were similar to those of Δ 9 -THC, which agrees with an earlier report that JWH-018 suppresses locomotor activity in mice (Wiley et al., 1998) .
In rats trained to discriminate Δ 9 -THC, all seven cannabinoids produced dose-dependent increases in drug-appropriate responding, indicating that they all share discriminative stimulus effects with Δ 9 -THC. This finding agrees with earlier reports that JWH-018 and JWH-073 substitute for Δ 9 -THC in rodents and monkeys Jarbe, 2011; Brents et al., 2013; Marshell et al., 2014; Wiley et al., 2014) . In addition, JWH-018 has been trained as a discriminative stimulus in monkeys, and Δ 9 -THC and JWH-073 fully substitute (Rodriguez and McMahon, 2014) . The discriminative stimulus effects of JWH-018 appear to be mediated by cannabinoid receptors because the cannabinoid receptor antagonist rimonabant blocked the discriminative stimulus effects of JWH-018, and the noncannabinoid sedatives ketamine (NMDA receptor blocker) and midazolam (benzodiazepine) failed to substitute (Rodriguez and McMahon, 2014) .
The synthetic cannabinoids produced a wide range of time courses for the discriminative stimulus effects, which may account for the varying reports of recreational users. Some users recording their experiences on websites such as Erowid.com or Bluelight.ru indicated that 'Spice' was very short-acting, whereas others reported very longacting effects. Of course, there is no way of knowing precisely what compounds such recreational users have taken, nor the dose; further, users often report concurrent use of other psychoactive compounds including caffeine, nicotine, antidepressants, etc. However, one case report of self-experimentation with 'Spice Diamond' indicated that it had noticeable effects more than 24 h after administration (Auwärter et al., 2009) . Chemical analysis revealed the presence of the two stereoisomers of a compound similar in structure to CP 47,497, with an additional carbon on the side chain. These findings indicate that compounds structurally related to CP 47,497 can produce very long-acting behavioral effects in humans.
In prior work with psychostimulants (e.g. Carroll et al., 2009; Gatch et al., 2013) , and to a somewhat lesser extent with serotonergic hallucinogens (Gatch et al., 2011) , mouse locomotor activity has been a useful predictor of dose range and pretreatment time in drug discrimination studies in rats. In these studies, the doses at which locomotor activity was suppressed also predicted the doses at which rate suppression would be observed in the drug discrimination assay. This was not the case for the cannabinoids tested in the present study. There was no relationship All of the cannabinoids fully substituted for the discriminative stimulus effects of Δ 9 -THC (>80% drug-appropriate responding). Δ 9 -THC, n = 13 rats; JWH-073, n = 7 rats; otherwise, n = 6, except where shown. *Rate different (P < 0.05) from vehicle control. Δ 9 -THC, Δ 9 -tetrahydrocannabinol.
Δ 9 -THC-like effects of K2/Spice compounds Gatch and Forster 755 between the time course of the locomotor depressant effects in mice and the time course of the discriminative stimulus effects. All of the test compounds produced a rapid onset of near-complete suppression of locomotor activity in mice, lasting 2-3 h, whereas the discriminative stimulus effects took anywhere between 5 min and 2 h to appear, and the peak effects lasted less than 30 min (JWH-203) to more than 8 h (CP 47,497-C8-homolog).
It is not clear why the locomotor depressant effects were uniform in onset and duration, whereas the time courses of the discriminative stimulus effects varied widely. Even though the ED 50 values for discrimination were less than or equal to the ED 50 values for locomotor activity, there was no relation between the magnitude or potency of the compounds depressing locomotor activity and the potency of discriminative stimulus effects or the incidence of rate depression in the discrimination assay (Table 1) . For example, the ED 50 values of the locomotor stimulant and the discriminative stimulus effects were very similar for CP 47,497-C8-homolog, which substantially suppressed operant responding. However, the potencies for the locomotor stimulant and the discriminative stimulus effects for JWH-018 were also quite similar, but JWH-018 showed no ratedecreasing effects. Further, JWH-073 suppressed operant responding, but its potency was six-fold less for its locomotor depressant effects than for its discriminative stimulus effects.
It is likely that the suppression of operant behavior reflects decreased motivation rather than merely suppression of the ability to move intentionally. However, this does not account for the wide range of time courses for the discriminative stimulus effects, especially as the response rate did not vary significantly during the time course studies (data not shown). It is also possible that the locomotor activity and the discriminative stimulus effects are mediated by different mechanisms; however, changes in both locomotor activity and drug discrimination induced by cannabinoids are blocked by the cannabinoid antagonist rimonabant (Craft et al., 2012; Katsidoni et al., 2013; Rodriguez and McMahon, 2014) . Finally, there may be a species difference in the pharmacokinetics of these cannabinoids between mice and rats, such that metabolism may take place at different rates. Unfortunately, little has been published on the metabolism of these compounds, especially with regard to species differences.
Taken together, these findings indicate that these seven synthetic cannabinoids (JWH-018, JWH-073, JWH-200, JWH-203, JWH-250, AM-2201, and CP 47,497-C8-homolog) are indeed behaviorally active, produce similar discriminative stimulus effects as Δ 9 -THC, and, therefore, may have a similar abuse liability as Δ 9 -THC. One study has examined the effects of JWH-018 on conditioned place preference . JWH-018 produced a conditioned aversion in naive mice, but produced a conditioned preference at low doses in mice previously exposed to Δ 9 -THC. Further conditioned place preference and selfadministration studies will be necessary to test whether the remainder of these compounds are reinforcing and will maintain drug seeking in animal models. Surveys of recreational users would be useful to assess whether these compounds produce different effects in naive versus marijuana-experienced human users.
